Anatara Lifesciences Ltd (ASX: ANR) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Anatara Lifesciences Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$3.14 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
313.59 million
Earnings per share
-0.010
Dividend per share
N/A
Year To Date Return
-21.43%
Earnings Yield
N/A
Franking
-
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Anatara Lifesciences Ltd (ASX: ANR)
Latest News
Share Market News
Why the Anatara (ASX:ANR) share price is rocketing 19% today
⏸️ Investing
5 multi-million dollar takeover targets
⏸️ Investing
Ham and pineapple could make Anatara Lifesciences Ltd the next CSL Limited
⏸️ Investing
10 stocks up by more than 50% in the past month
ANR ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Anatara Lifesciences Ltd
Anatara Lifesciences Ltd. engages in the development of non-antibiotic oral solutions for gastrointestinal diseases in animals and humans. It also develops and commercializes Detach, a non-antibiotic therapy that prevents and treats diarrhea in piglets. The company was founded by Tracey Mynott on July 15, 2010 and is headquartered in North Melbourne, Australia.
ANR Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 05 Feb 2026 | $0.01 | $0.00 | 0.00% | 95,000 | $0.01 | $0.01 | $0.01 |
| 04 Feb 2026 | $0.01 | $0.00 | 0.00% | 42,693 | $0.01 | $0.01 | $0.01 |
| 02 Feb 2026 | $0.01 | $0.00 | 0.00% | 1,400,000 | $0.01 | $0.01 | $0.01 |
| 30 Jan 2026 | $0.01 | $0.00 | 0.00% | 2,100,228 | $0.01 | $0.01 | $0.01 |
| 28 Jan 2026 | $0.01 | $0.00 | 0.00% | 71,428 | $0.01 | $0.01 | $0.01 |
| 23 Jan 2026 | $0.01 | $0.00 | 0.00% | 847,730 | $0.01 | $0.01 | $0.01 |
| 22 Jan 2026 | $0.01 | $0.00 | 0.00% | 150,000 | $0.01 | $0.01 | $0.01 |
| 21 Jan 2026 | $0.01 | $0.00 | 0.00% | 312,300 | $0.01 | $0.01 | $0.01 |
| 20 Jan 2026 | $0.01 | $0.00 | 0.00% | 20,391 | $0.01 | $0.01 | $0.01 |
| 19 Jan 2026 | $0.01 | $0.00 | 0.00% | 118 | $0.01 | $0.01 | $0.01 |
| 16 Jan 2026 | $0.01 | $0.00 | 0.00% | 1,674,453 | $0.01 | $0.01 | $0.01 |
| 15 Jan 2026 | $0.01 | $0.00 | 0.00% | 181,818 | $0.01 | $0.01 | $0.01 |
| 14 Jan 2026 | $0.01 | $0.00 | 0.00% | 477,240 | $0.01 | $0.01 | $0.01 |
| 13 Jan 2026 | $0.01 | $0.00 | 0.00% | 8,164 | $0.01 | $0.01 | $0.01 |
| 12 Jan 2026 | $0.01 | $0.00 | 0.00% | 270,000 | $0.01 | $0.01 | $0.01 |
| 09 Jan 2026 | $0.01 | $0.00 | 0.00% | 400,000 | $0.01 | $0.01 | $0.01 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 11 Dec 2025 | David Brookes | Expiry | 932,143 | $11,185 |
Options expired. As per announement on 11-12-2025
|
| 11 Dec 2025 | John Michailidis | Expiry | 250,000 | $3,000 |
Options expired.
|
| 11 Dec 2025 | Dirk Dissel | Expiry | 2,350,001 | $28,200 |
Options expired.
|
| 26 Nov 2025 | David Brookes | Issued | 3,333,334 | $40,000 |
Placement.
|
| 26 Nov 2025 | Dirk Dissel | Issued | 3,333,333 | $40,000 |
Placement.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Dr David Lionel Brookes | Executive ChairmanExecutive Director | Jun 2022 |
Dr Brookes has experience in the health and biotechnology industries, first becoming involved in the biotechnology sector in the late 1990's as an analyst. He is member of risk management committee.
|
| Mr John Michailidis | Chief Operating OfficerExecutive Director | Oct 2023 |
Mr Michailidis has over 30 years of experience in the healthcare, pharmaceutical and biotechnology industries both in Australia and internationally. He has a record in business transformation, entrepreneurship, translation and commercialisation of science organisations, government engagement and influence, effectiveness in research translation, business development and organisational responsibility. He is also chair of risk management committee.
|
| Mr Dirk van Dissel | Non-Executive Director | Sep 2025 |
Mr Dissel has more than 20 years experience in private equity, boutique investment banking and stockbroking. He has provided corporate advisory services and equity capital markets solutions to micro-cap and small-cap companies across the life sciences (biotechnology and healthcare), industrial technology, information and mobile technology, and resources sectors. He has also advised on numerous buy-side and sell-side transactions.
|
| Mr Jonathan William Lindh | Company Secretary | Nov 2024 |
-
|
| Simon Erskine | Chief Development Officer |
-
|
|
| Jonathan William Lindh | Company Secretary |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| RTL Group Investments Pty Ltd <The RTL Investment A/C> | 22,000,000 | 8.90% |
| UBS Nominees Pty Ltd | 21,607,763 | 8.74% |
| Mr David Dominic Pevcic | 11,175,986 | 4.52% |
| Scintilla Strategic Investments Limited | 8,628,879 | 3.49% |
| Mr Sufian Ahmad | 7,325,517 | 2.96% |
| RTL Group Investments Pty Ltd <The RTL Investment A/C> i | 7,000,000 | 2.83% |
| Parma Corporation Pty Ltd | 5,576,771 | 2.26% |
| Netwealth Investments Limited <Wrap Services A/C> | 5,300,000 | 2.14% |
| Tarandi 1996 Pty Ltd <Dr Dl Brookes Super A/C> | 5,290,002 | 2.14% |
| Mrs Ifrah Nishat | 5,206,857 | 2.11% |
| Toucan Trading Pty Ltd | 4,876,353 | 1.97% |
| Myeng Pty Ltd | 3,580,211 | 1.45% |
| BRSB Super Fund Pty Ltd <BRSB Super Fund A/C> | 3,450,000 | 1.40% |
| 10 Bolivianos Pty Ltd | 3,271,293 | 1.32% |
| Mr John Gerard O Malley | 3,119,655 | 1.26% |
| Lake Pacific Pty Ltd | 2,934,655 | 1.19% |
| Mousetrap Nominees Pty Ltd <Michael Whiting Family A/C> | 2,623,103 | 1.06% |
| Mr Andre Nicholas Marschke and Mrs Shaleah Ann Marschke <Anm S/F A/C> | 2,600,000 | 1.05% |
| Lyndahl Nominees Pty Ltd <W A Dahlsen Super Fund A/C> | 2,523,862 | 1.02% |
| Mr Gabriel Govinda | 2,500,000 | 1.01% |
